Seer Appoints Deep Nishar and Mostafa Ronaghi, Ph.D. to its Board of Directors
February 17 2021 - 8:00AM
Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing
a disruptive new platform for proteomics, today announced it has
appointed Deep Nishar and Mostafa Ronaghi, Ph.D. to serve on its
Board of Directors, effective February 13, 2020. Mr. Nishar is
currently a Senior Managing Partner at SoftBank Investment Advisers
(SBIA) in Silicon Valley and brings more than 20 years of
experience building and growing software and internet companies,
including Google and LinkedIn. Dr. Ronaghi is the former Chief
Technology Officer at Illumina, a co-founder of Grail, and a
current Scientific Advisory Board member of Seer with decades of
experience founding breakthrough technology companies.
“We’re delighted to welcome Deep and Mostafa to our Board of
Directors as we scale to open up a new gateway to the proteome.
Deep and Mostafa are seasoned leaders who have built global,
high-impact, transformational companies,” said Omid Farokhzad,
M.D., Chair, Chief Executive Officer and Founder of Seer. “Their
unique and complimentary perspectives on technology expansion,
health care innovation, and ecosystem creation will be invaluable
to Seer as we accelerate and expand our markets.”
“I am honored to join the board of Seer, an innovative
company enabling unbiased deep proteomics at a scale and speed
to match genomics. Detecting proteins at the amino acid level
in an unbiased way that narrower proteomics approaches miss is
opening up proteogenomics and enabling the discovery of new
biomarkers, new drug targets and potentially entirely new markets,”
said Mr. Nishar. “As the field of proteomics continues to see
significant growth, I look forward to partnering with Seer’s
talented leadership team as they aim to deliver on the
remarkable promise of the technology to profoundly impact our
understanding of biology and human health through proteomics and
proteogenomics."
“I’m very excited for the opportunity to deepen my relationship
with Seer and to continue to advance its goal of pioneering
unbiased, deep proteomics at scale,” said Dr. Ronaghi. “Genomics
has laid a powerful foundation for our understanding of human
health, but the proteome is the next frontier in biological
insight. As an early investor and scientific advisor, my enthusiasm
for this technology and its applications continues to grow, not
only across proteomics but also in genomics. Seer’s unbiased
platform can uniquely enable a speed and scale that will accelerate
the functional characterization of the hundreds of millions of
genetic variants that have been identified via genomics.”
Mr. Nishar has more than 20 years of experience in helping build
and grow software and internet businesses. Prior to joining
SoftBank, Deep served as Senior Vice President of Products and User
Experience at LinkedIn. He also held senior executive roles at
Google and was previously the Founder of enterprise software
company Patkai Networks. He currently sits on the board of
directors of a number of different companies, including Relay
Therapeutics and Vir Bio.
Dr. Ronaghi served as Senior Vice President of Entrepreneurial
Development, Senior Vice President and CTO during his decade-plus
time at Illumina, where he was responsible for leading Illumina’s
internal research and technology, co-founded GRAIL and the Illumina
Accelerator, the world’s first business accelerator focused solely
on the creation of an innovation ecosystem for the genomics
industry. Dr. Ronaghi has also co-founded multiple companies,
including Avantome, NextBio, ParAllele Bioscience, and
Pyrosequencing.
About Seer
Seer™ is a life sciences company focused on enabling exceptional
scientific outcomes by commercializing transformative products that
will drive breakthrough ideas by unlocking the deep, unbiased
biological information that can make them a reality. Seer is
developing its Proteograph™ Product Suite, which is an integrated
solution consisting of consumables, automation instrumentation and
proprietary software that performs deep, unbiased proteomics
analysis at scale in a matter of hours. Seer designed the
Proteograph to be efficient and easy-to-use, leveraging widely
adopted laboratory instrumentation to provide a decentralized
solution broadly available to life sciences researchers. Seer’s
Proteograph Product Suite is for research use only and is not
intended for diagnostic procedures. For more information, please
visit www.seer.bio.
Investor ContactCarrie
Mendivilinvestor@seer.bio
Media ContactKaren Possematopr@seer.bio
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/f01190ac-bcab-4091-afcb-6b40e894b8e5
https://www.globenewswire.com/NewsRoom/AttachmentNg/13c7c43d-850c-4a46-a7fa-b51442b80cad
Seer (NASDAQ:SEER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Seer (NASDAQ:SEER)
Historical Stock Chart
From Jul 2023 to Jul 2024